<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01154790</url>
  </required_header>
  <id_info>
    <org_study_id>CG100649-1-04</org_study_id>
    <nct_id>NCT01154790</nct_id>
  </id_info>
  <brief_title>Phase I Study on Multiple Oral Dosing of CG100649</brief_title>
  <official_title>A Randomized, Double-blind Study Evaluating the Upper Gastrointestinal Safety on Multiple Doses of CG100649 in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CrystalGenomics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CrystalGenomics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the safety, tolerability, and pharmacokinetics of
      3 escalating loading and maintenance dose regimens of CG100649 administered orally for 7
      total days in healthy volunteers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Data dictionary that contains detailed descriptions of each variable used by the registry,
      including the source of the variable, coding information if used CTCAE and normal ranges if
      relevant.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2010</start_date>
  <completion_date type="Actual">January 2011</completion_date>
  <primary_completion_date type="Actual">January 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety (normal results for safety tests)</measure>
    <time_frame>27days</time_frame>
    <description>Cardiovascular: BP,ECG, Holter monitoring
GI: Fecal occult blood
Kidney: Urine electrolyte test
Adverse events
Physical examination, vital signs</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">120</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>CG100649</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>By the amount of doses, the groups are classified</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Naproxen</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>By the amount of doses, the groups are classified</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>By the amount of doses, the groups are classified</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CG100649</intervention_name>
    <description>6 subjects: study drug 2 subjects: placebo</description>
    <arm_group_label>CG100649</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>6 subjects: study drug 2 subjects: placebo</description>
    <arm_group_label>CG100649</arm_group_label>
    <arm_group_label>Naproxen</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Naproxen</intervention_name>
    <description>6 subjects: study drug 2 subjects: placebo</description>
    <arm_group_label>Naproxen</arm_group_label>
    <other_name>NAXEN</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. 19-55 years old. Body weight is over 50 kg (male) and over 45 kg (female). Body
             weights must be within 20% of ideal body weight for their height according to the
             ideal body weight table.

          2. No significant congenital/chronic disease. No symptoms in physical examination.

          3. Appropriate subjects as determined by past medical history, laboratory tests, serology
             and urinalysis.

          4. Be able to understand the objective, method of the study, the characteristics of
             investigational drug, and comply with the requirement of the study. Subject must
             provide written informed consent prior to study participation.

        Exclusion Criteria:

          1. History or presence of liver, kidney, or nervous system disease, respiratory
             disorders, endocrinological disorders, hemato-oncologic, cardiovascular or psychiatric
             or cognitive disorders.

          2. History of gastrointestinal disorders (bleeding, ulceration, hemorrhoids, piles) or
             disorders of absorption, distribution, metabolism, excretion.

          3. History of known hypersensitivity to drugs including CG100649.

          4. After taking a rest in sitting position for 3 minutes, subjects who have low blood
             pressure (Systolic BP ≤ 90 mmHg or Diastolic BP ≤ 50 mmHg) or high blood pressure
             (Systolic BP ≥ 150 mmHg or Diastolic BP ≥ 100 mmHg).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Seonggu Ro</last_name>
    <role>Study Director</role>
    <affiliation>CrystalGenomics, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>June 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 16, 2010</study_first_submitted>
  <study_first_submitted_qc>June 30, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 1, 2010</study_first_posted>
  <last_update_submitted>January 26, 2016</last_update_submitted>
  <last_update_submitted_qc>January 26, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 28, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>healthy volunteers</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Naproxen</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

